EUCTR2020-006118-19-ITActive, not recruitingPhase 1
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe - 2020-012-00EU1
Hutchison MediPharma Limited0 sites76 target enrollmentStarted: June 8, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 76
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Has histologically or cytologically documented, locally advanced, or metastatic NET and has progressed on at least 1 prior line of therapy, but no more than 3 therapies:
- •a. Cohort A: NET of lung origin
- •b. Cohort B: NET of small bowel origin
- •c. Cohort C: NET of non-small bowel, non-pancreas, and non-lung origin
- •d. Cohort D (DDI substudy): NET of any origin
- •2. Has radiologic evidence of progressive tumour within 12 months of study enrolment
- •3. Is willing and able to provide informed consent
- •4. Is =18 years of age
- •5. Has measurable lesions according to RECIST Version 1.1
- •6. Has absolute neutrophil count of = 1.5×109/L, platelet count of = 100×109/L, and haemoglobin = 9 g/dL
- •7. Has serum total bilirubin <1.5 times the upper limit of normal (ULN)
- •8. Has proteinuria <2+ by urinalysis, or 24-hour urine collection =1 g of protein, or urine protein: urine-creatinine ratio =1.9
- •9. Has alanine aminotransferase (ALT), AST, or alkaline phosphatase levels = 2.5 times the ULN
- •a. Patients with known liver metastases may have ALT, AST, and ALP = 3× the ULN 10. Has serum creatinine <1.5 times ULN or creatinine clearance = 60 mL/min
- •11. International normalised ratio (INR) >1.5 or activated partial thromboplastin time (aPTT) >1.5×ULN
- •12. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •13. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception that results in a low failure rate (<1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug. Such methods include oral hormonal contraception (combined estrogen/progestogen or progestogen only) or highly effective non-oral hormonal contraception (e.g., Depo-Provera and Implanon) associated with inhibition of ovulation together with a barrier method (e.g., diaphragm, always containing a spermicide), intrauterine device, intrauterine hormone-releasing system, bilateral tubal ligation, vasectomized partner, or sexual abstinence in line with the preferred and usual lifestyle of the subject. Oral and non-oral hormonal contraception should always be combined with an additional contraceptive method (i.e., barrier method) because of a potential interaction with the study drug. The same criteria are applicable to male patients involved in this clinical study if they have a partner of childbirth potential, and male patients must always use a condom.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 38
Exclusion Criteria
- •1. Has an AE due to previous anti-tumour therapy that has not recovered to =CTCAE Grade 1, except alopecia and peripheral neurotoxicity with = CTCAE Grade 2 caused by platinum chemotherapy
- •2. Major surgery within previous 4 weeks or radiation therapy within 2 weeks prior to the start of treatment. Prior palliative radiotherapy for metastatic lesions is permitted if there is at least one measurable lesion that has not been irradiated.
- •3. Prior VEGF/VEGFR-targeted therapy
- •4. Has uncontrollable hypertension, defined as systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg, despite antihypertensive medication
- •5. PT/INR >1.5 or activated partial thromboplastin time (aPTT) >1.5×ULN. For patients on Coumadin or coumadin-like products, please refer to Section 7.3.3)
- •6. Has gastrointestinal disease or condition within 6 months prior to first dose that investigators suspect may affect drug absorption, including, but not limited to, active gastric and duodenal ulcers, ulcerative colitis and other digestive disease, gastrointestinal tumour with active bleeding, or other gastrointestinal conditions that
- •could, in the investigators judgment, result in bleeding or perforation
- •7. Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks) within 6 months of first dose of study drug
- •8. Has clinically significant cardiovascular disease, including, but not limited to, acute myocardial infarction within 6 months prior to enrolment, severe/unstable angina pectoris or coronary artery bypass grafting, congestive heart failure =2 according to the New York Heart Association classification, ventricular arrhythmia that needs drug treatment, and left ventricular ejection fraction (LVEF) <50%
- •9. Has a mean corrected QT interval by Fridericia (QTcF) =480 ms
- •10. Has brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded
- •11. Has a high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators
- •12. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 6 months prior to first dose of study drug
- •13. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of surufatinib
- •14. For Cohort D, use of medications that are known substrates, inhibitors, or inducers of CYP3A or substrates of P-gp or BCRP within 3 weeks before the first dose of the drug cocktail
- •15. Prior history of other cancer except those treated with curative intent for in situ non-melanoma skin cancer, breast, or cervical cancer, or those treated with curative intent and no evidence of disease in the last 5 years prior to enrolment in the study
- •16. Has a clinically meaningful ongoing infection
- •17. Has clinical symptoms consistent with pancreatitis
- •18. Has a history of allergies to any ingredient of surufatinib or its capsule shell,
- •including tartrazine (E 102)
Investigators
Similar Trials
Active, not recruiting
Phase 1
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europeeuroendocrine TumoursMedDRA version: 21.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-006118-19-DEHutchison MediPharma Limited76
Recruiting
Phase 1
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in EuropeEUCTR2020-006118-19-FRHutchison MediPharma Limited76
Active, not recruiting
Phase 1
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in EuropeEUCTR2020-006118-19-ESHutchison MediPharma Limited76
Active, not recruiting
Phase 1
Surufatinib in Combination With Tislelizumab in Advanced Solid TumorsEUCTR2020-004163-12-ESHutchison MediPharma Limited107
Terminated
Phase 2
Open-Label Surufatinib in European Patients With NETNeuroendocrine TumoursNeuroendocrine Tumour of the LungSmall Intestinal NETNCT04579679Hutchmed78